

Annett Linge

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2220268/publications.pdf>

Version: 2024-02-01

74
papers

2,252
citations

279487

23
h-index

223531

46
g-index

79
all docs

79
docs citations

79
times ranked

4169
citing authors

#	ARTICLE	IF	CITATIONS
1	Cancer stem cells: Radioresistance, prediction of radiotherapy outcome and specific targets for combined treatments. <i>Advanced Drug Delivery Reviews</i> , 2017, 109, 63-73.	6.6	247
2	CD8+ tumour-infiltrating lymphocytes in relation to HPV status and clinical outcome in patients with head and neck cancer after postoperative chemoradiotherapy: A multicentre study of the German cancer consortium radiation oncology group (DKTK-ROG). <i>International Journal of Cancer</i> , 2016, 138, 171-181.	2.3	184
3	A comparative study of machine learning methods for time-to-event survival data for radiomics risk modelling. <i>Scientific Reports</i> , 2017, 7, 13206.	1.6	163
4	HPV16 DNA status is a strong prognosticator of loco-regional control after postoperative radiochemotherapy of locally advanced oropharyngeal carcinoma: Results from a multicentre explorative study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG). <i>Radiotherapy and Oncology</i> , 2014, 113, 317-323.	0.3	141
5	HPV status, cancer stem cell marker expression, hypoxia gene signatures and tumour volume identify good prognosis subgroups in patients with HNSCC after primary radiochemotherapy: A multicentre retrospective study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG). <i>Radiotherapy and Oncology</i> , 2016, 121, 364-373.	0.3	130
6	Low Cancer Stem Cell Marker Expression and Low Hypoxia Identify Good Prognosis Subgroups in HPV(+) HNSCC after Postoperative Radiochemotherapy: A Multicenter Study of the DKTK-ROG. <i>Clinical Cancer Research</i> , 2016, 22, 2639-2649.	3.2	127
7	The PD-1/PD-L1 axis and human papilloma virus in patients with head and neck cancer after adjuvant chemoradiotherapy: A multicentre study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG). <i>International Journal of Cancer</i> , 2017, 141, 594-603.	2.3	91
8	Subjugation of TGF β 2 Signaling by Human Papilloma Virus in Head and Neck Squamous Cell Carcinoma Shifts DNA Repair from Homologous Recombination to Alternative End Joining. <i>Clinical Cancer Research</i> , 2018, 24, 6001-6014.	3.2	71
9	GLS-driven glutamine catabolism contributes to prostate cancer radiosensitivity by regulating the redox state, stemness and ATG5-mediated autophagy. <i>Theranostics</i> , 2021, 11, 7844-7868.	4.6	70
10	A Five-MicroRNA Signature Predicts Survival and Disease Control of Patients with Head and Neck Cancer Negative for HPV Infection. <i>Clinical Cancer Research</i> , 2019, 25, 1505-1516.	3.2	67
11	Comparative analysis of transcriptomics based hypoxia signatures in head- and neck squamous cell carcinoma. <i>Radiotherapy and Oncology</i> , 2016, 118, 350-358.	0.3	62
12	Targeted next-generation sequencing of locally advanced squamous cell carcinomas of the head and neck reveals druggable targets for improving adjuvant chemoradiation. <i>European Journal of Cancer</i> , 2016, 57, 78-86.	1.3	62
13	Interference of tumour mutational burden with outcome of patients with head and neck cancer treated with definitive chemoradiation: a multicentre retrospective study of the German Cancer Consortium Radiation Oncology Group. <i>European Journal of Cancer</i> , 2019, 116, 67-76.	1.3	58
14	SLC3A2/CD98hc, autophagy and tumor radioresistance: a link confirmed. <i>Autophagy</i> , 2019, 15, 1850-1851.	4.3	56
15	Differential Expression of Fourteen Proteins between Uveal Melanoma from Patients Who Subsequently Developed Distant Metastases versus Those Who Did Not. , 2012, 53, 4634.		54
16	The CD98 Heavy Chain Is a Marker and Regulator of Head and Neck Squamous Cell Carcinoma Radiosensitivity. <i>Clinical Cancer Research</i> , 2019, 25, 3152-3163.	3.2	53
17	Heat shock protein 70 and tumor-infiltrating NK cells as prognostic indicators for patients with squamous cell carcinoma of the head and neck after radiochemotherapy: A multicentre retrospective study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG). <i>International Journal of Cancer</i> , 2018, 142, 1911-1925.	2.3	50
18	Development and Validation of a Gene Signature for Patients with Head and Neck Carcinomas Treated by Postoperative Radio(chemo)therapy. <i>Clinical Cancer Research</i> , 2018, 24, 1364-1374.	3.2	45

#	ARTICLE	IF	CITATIONS
19	Downregulation of caveolin-1 affects bleomycin-induced growth arrest and cellular senescence in A549 cells. <i>International Journal of Biochemistry and Cell Biology</i> , 2007, 39, 1964-1974.	1.2	42
20	2D and 3D convolutional neural networks for outcome modelling of locally advanced head and neck squamous cell carcinoma. <i>Scientific Reports</i> , 2020, 10, 15625.	1.6	34
21	Independent validation of tumour volume, cancer stem cell markers and hypoxia-associated gene expressions for HNSCC after primary radiochemotherapy. <i>Clinical and Translational Radiation Oncology</i> , 2019, 16, 40-47.	0.9	32
22	Characterization of the molecular interaction between caveolin-1 and the P2X receptors 4 and 7 in E10 mouse lung alveolar epithelial cells. <i>International Journal of Biochemistry and Cell Biology</i> , 2008, 40, 2230-2239.	1.2	29
23	Identification and Functional Validation of RAD23B as a Potential Protein in Human Breast Cancer Progression. <i>Journal of Proteome Research</i> , 2014, 13, 3212-3222.	1.8	28
24	Oct4 confers stemness and radioresistance to head and neck squamous cell carcinoma by regulating the homologous recombination factors PSMC3IP and RAD54L. <i>Oncogene</i> , 2021, 40, 4214-4228.	2.6	27
25	Repeat FMISO-PET imaging weakly correlates with hypoxia-associated gene expressions for locally advanced HNSCC treated by primary radiochemotherapy. <i>Radiotherapy and Oncology</i> , 2019, 135, 43-50.	0.3	25
26	SDF-1/CXCR4 expression is an independent negative prognostic biomarker in patients with head and neck cancer after primary radiochemotherapy. <i>Radiotherapy and Oncology</i> , 2018, 126, 125-131.	0.3	24
27	Independent validation of the prognostic value of cancer stem cell marker expression and hypoxia-induced gene expression for patients with locally advanced HNSCC after postoperative radiotherapy. <i>Clinical and Translational Radiation Oncology</i> , 2016, 1, 19-26.	0.9	22
28	EGFR-amplification plus gene expression profiling predicts response to combined radiotherapy with EGFR-inhibition: A preclinical trial in 10 HNSCC-tumour-xenograft models. <i>Radiotherapy and Oncology</i> , 2017, 124, 496-503.	0.3	21
29	Comprehensive Analysis of Tumour Sub-Volumes for Radiomic Risk Modelling in Locally Advanced HNSCC. <i>Cancers</i> , 2020, 12, 3047.	1.7	19
30	Comparison of detection methods for HPV status as a prognostic marker for loco-regional control after radiochemotherapy in patients with HNSCC. <i>Radiotherapy and Oncology</i> , 2018, 127, 27-35.	0.3	17
31	Increased P2X7R expression in atrial cardiomyocytes of caveolin-1 deficient mice. <i>Histochemistry and Cell Biology</i> , 2010, 134, 31-38.	0.8	16
32	SDF-1/CXCR4 expression in head and neck cancer and outcome after postoperative radiochemotherapy. <i>Clinical and Translational Radiation Oncology</i> , 2017, 5, 28-36.	0.9	16
33	Final Results of the Prospective Biomarker Trial PETra: [11C]-MET-Accumulation in Postoperative PET/MRI Predicts Outcome after Radiochemotherapy in Glioblastoma. <i>Clinical Cancer Research</i> , 2021, 27, 1351-1360.	3.2	15
34	PRDX3 is associated with metastasis and poor survival in uveal melanoma. <i>Journal of Clinical Pathology</i> , 2020, 73, 408-412.	1.0	11
35	Bleomycin treatment of A549 human lung cancer cells results in association of MGr1-Ag and caveolin-1 in lipid rafts. <i>International Journal of Biochemistry and Cell Biology</i> , 2011, 43, 98-105.	1.2	10
36	Successful immunotherapy and irradiation in a HIV-positive patient with metastatic Merkel cell carcinoma. <i>Clinical and Translational Radiation Oncology</i> , 2019, 15, 42-45.	0.9	10

#	ARTICLE	IF	CITATIONS
37	Comparison of GeneChip, nCounter, and Real-Time PCR-Based Gene Expressions Predicting Locoregional Tumor Control after Primary and Postoperative Radiochemotherapy in Head and Neck Squamous Cell Carcinoma. <i>Journal of Molecular Diagnostics</i> , 2020, 22, 801-810.	1.2	10
38	Bleomycin induces caveolin-1 and -2 expression in epithelial lung cancer A549 cells. <i>Anticancer Research</i> , 2007, 27, 1343-51.	0.5	10
39	Establishment and Characterisation of Heterotopic Patient-Derived Xenografts for Glioblastoma. <i>Cancers</i> , 2020, 12, 871.	1.7	9
40	Tyrosine Kinase c-MET as Therapeutic Target for Radiosensitization of Head and Neck Squamous Cell Carcinomas. <i>Cancers</i> , 2021, 13, 1865.	1.7	9
41	Comparison of the composition of lymphocyte subpopulations in non-relapse and relapse patients with squamous cell carcinoma of the head and neck before, during radiochemotherapy and in the follow-up period: a multicenter prospective study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG). <i>Radiation Oncology</i> , 2021, 16, 141.	1.2	9
42	Definition and validation of a radiomics signature for loco-regional tumour control in patients with locally advanced head and neck squamous cell carcinoma. <i>Clinical and Translational Radiation Oncology</i> , 2021, 26, 62-70.	0.9	8
43	Plasticity within Aldehyde Dehydrogenase-Positive Cells Determines Prostate Cancer Radiosensitivity. <i>Molecular Cancer Research</i> , 2022, 20, 794-809.	1.5	8
44	Validation of CD98hc as a Therapeutic Target for a Combination of Radiation and Immunotherapies in Head and Neck Squamous Cell Carcinoma. <i>Cancers</i> , 2022, 14, 1677.	1.7	7
45	Specific requirements for translation of biological research into clinical radiation oncology. <i>Molecular Oncology</i> , 2020, 14, 1569-1576.	2.1	6
46	ERCC2 gene single-nucleotide polymorphism as a prognostic factor for locally advanced head and neck carcinomas after definitive cisplatin-based radiochemotherapy. <i>Pharmacogenomics Journal</i> , 2021, 21, 37-46.	0.9	6
47	Analyses of molecular subtypes and their association to mechanisms of radioresistance in patients with HPV-negative HNSCC treated by postoperative radiochemotherapy. <i>Radiotherapy and Oncology</i> , 2022, 167, 300-307.	0.3	5
48	Biomarker signatures for primary radiochemotherapy of locally advanced HNSCC - Hypothesis generation on a multicentre cohort of the DKTK-ROG. <i>Radiotherapy and Oncology</i> , 2022, 169, 8-14.	0.3	5
49	Molecular Response to Combined Molecular- and External Radiotherapy in Head and Neck Squamous Cell Carcinoma (HNSCC). <i>Cancers</i> , 2021, 13, 5595.	1.7	4
50	Development and validation of a 6-gene signature for the prognosis of loco-regional control in patients with HPV-negative locally advanced HNSCC treated by postoperative radio(chemo)therapy. <i>Radiotherapy and Oncology</i> , 2022, 171, 91-100.	0.3	4
51	Assessment of gene expressions from squamous cell carcinoma of the head and neck to predict radiochemotherapy-related xerostomia and dysphagia. <i>Acta Oncologica</i> , 2022, 61, 856-863.	0.8	4
52	Mutational patterns of HPV+ and HPV- squamous cell carcinomas of the head and neck (SCCHN) and their interference with outcome after adjuvant chemoradiation: A multicenter biomarker study of the German Cancer Consortium Radiation Oncology Group.. <i>Journal of Clinical Oncology</i> , 2015, 33, 6006-6006.	0.8	3
53	Do We Need Complex Image Features to Personalize Treatment of Patients with Locally Advanced Rectal Cancer?. <i>Lecture Notes in Computer Science</i> , 2021, , 775-785.	1.0	2
54	Discovery of a reliable and robust methylome classifier of HPV driven head and neck cancer with favorable response to chemoradiation: A multicenter study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG).. <i>Journal of Clinical Oncology</i> , 2018, 36, 6019-6019.	0.8	2

#	ARTICLE	IF	CITATIONS
55	Interference between mutational load, immune signatures and outcome in patients with head and neck cancer treated with definitive chemoradiation: A multicenter study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG).. <i>Journal of Clinical Oncology</i> , 2018, 36, 6047-6047.	0.8	2
56	HPV and beyond-looking out for biomarkers for distinguishing the good prognosis from the bad prognosis group in locally advanced and clinically high risk HNSCC. <i>Annals of Translational Medicine</i> , 2015, 3, 255.	0.7	2
57	Tumor DNA Methylome derived Epigenetic Fingerprint Identifies HPV negative Head and Neck Patients at Risk for Locoregional Recurrence after Postoperative Radiochemotherapy. <i>International Journal of Cancer</i> , 2021, 150, 603.	2.3	2
58	A Novel 2-Metogene Signature to Identify High-Risk HNSCC Patients amongst Those Who Are Clinically at Intermediate Risk and Are Treated with PORT. <i>Cancers</i> , 2022, 14, 3031.	1.7	2
59	OC-0152: Glutamine metabolism as potential biomarker and target for prostate cancer radiosensitization. <i>Radiotherapy and Oncology</i> , 2018, 127, S76-S77.	0.3	1
60	Importance of long-term follow up to address long-term effectiveness and toxicity of radiotherapy. <i>Radiotherapy and Oncology</i> , 2022, 170, 1-3.	0.3	1
61	Corrigendum to "HPV16 DNA status is a strong prognosticator of loco-regional control after postoperative radiochemotherapy of locally advanced oropharyngeal carcinoma: Results from a multicentre explorative study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG)" [<i>Radiother. Oncol.</i> 113 (2014) 317-323]. <i>Radiotherapy and Oncology</i> , 2015, 114, 419.	0.3	0
62	The Role of Cancer Stem Cells in Tumour Radioresponse. , 2016, , 43-74.		0
63	PO-0619: Comparison of a nanoString and RNA microarray gene signature predicting LRC after PORT-C in HNSCC. <i>Radiotherapy and Oncology</i> , 2017, 123, S323-S324.	0.3	0
64	PO-119 Accelerated glutamine metabolism is conferring radioresistance to prostate cancer. <i>ESMO Open</i> , 2018, 3, A272-A273.	2.0	0
65	OC-0324: Immune contexture in SCCHN and outcome after chemoradiotherapy in an uni- and multicentric cohort. <i>Radiotherapy and Oncology</i> , 2018, 127, S172-S173.	0.3	0
66	OC-0496 Deep-learning based estimation of locoregional control for patients with locally advanced HNSCC. <i>Radiotherapy and Oncology</i> , 2019, 133, S254-S255.	0.3	0
67	A Methylome Classifier Identifies Patients at Risk for Locoregional Recurrence after Adjuvant Radiochemotherapy in HPV-DNA negative HNSCC: a Multicenter Trial of the German Cancer Consortium- Radiation Oncology Group (DKTK-ROG). <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 105, S17-S18.	0.4	0
68	The Pluripotency Transcription Factor Oct4 Contributes to Head and Neck Squamous Cell Carcinoma Radioresistance via Regulation of DNA Repair and the Stem Cell Phenotype. <i>Medical Sciences Forum</i> , 2021, 3, .	0.5	0
69	OC-0062 Potential predictive biomarkers for Nimorazole-modified radiochemotherapy in head and neck cancer. <i>Radiotherapy and Oncology</i> , 2021, 161, S37-S38.	0.3	0
70	OC-0638 Integrated radiogenomics analyses for outcome prognosis in patients with locally advanced HNSCC. <i>Radiotherapy and Oncology</i> , 2021, 161, S503-S504.	0.3	0
71	OC-0277 A 6-gene signature for loco-regional control prognosis in HNSCC patients treated by PORT-C. <i>Radiotherapy and Oncology</i> , 2021, 161, S186-S187.	0.3	0
72	Connective tissue growth factor (CTGF) methylation status is associated with prognosis of patients with head and neck squamous cell carcinoma (HNSCC) treated with radiochemotherapy (RCHT): A multicenter study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG).. <i>Journal of Clinical Oncology</i> , 2019, 37, 6050-6050.	0.8	0

#	ARTICLE	IF	CITATIONS
73	PD-0066: A 24-miRNA signature predicting HPV status in head and neck cancer. Radiotherapy and Oncology, 2020, 152, S27-S28.	0.3	0
74	PO-1540: Radiomic models for validation in patients with locally advanced HNSCC treated with primary RTCx. Radiotherapy and Oncology, 2020, 152, S832-S833.	0.3	0